220 related articles for article (PubMed ID: 11704898)
1. [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].
Rao ML; Hiemke C; Grasmäder K; Baumann P;
Fortschr Neurol Psychiatr; 2001 Nov; 69(11):510-7. PubMed ID: 11704898
[TBL] [Abstract][Full Text] [Related]
2. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
[TBL] [Abstract][Full Text] [Related]
3. Influence of fluoxetine on olanzapine pharmacokinetics.
Gossen D; de Suray JM; Vandenhende F; Onkelinx C; Gangji D
AAPS PharmSci; 2002; 4(2):E11. PubMed ID: 12102620
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine. Pharmacokinetic and pharmacodynamic profile.
Callaghan JT; Bergstrom RF; Ptak LR; Beasley CM
Clin Pharmacokinet; 1999 Sep; 37(3):177-93. PubMed ID: 10511917
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes.
Hägg S; Spigset O; Lakso HA; Dahlqvist R
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):493-7. PubMed ID: 11699614
[TBL] [Abstract][Full Text] [Related]
6. Focus on olanzapine.
Green B
Curr Med Res Opin; 1999; 15(2):79-85. PubMed ID: 10494490
[TBL] [Abstract][Full Text] [Related]
7. [Monitoring of serum olanzapine during antipsychotic treatment].
Linnet K; Olesen OV
Ugeskr Laeger; 2000 Sep; 162(36):4802-5. PubMed ID: 10994377
[TBL] [Abstract][Full Text] [Related]
8. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.
Hiemke C; Peled A; Jabarin M; Hadjez J; Weigmann H; Härtter S; Modai I; Ritsner M; Silver H
J Clin Psychopharmacol; 2002 Oct; 22(5):502-6. PubMed ID: 12352274
[TBL] [Abstract][Full Text] [Related]
9. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers.
Markowitz JS; Devane CL; Liston HL; Boulton DW; Risch SC
Clin Pharmacol Ther; 2002 Jan; 71(1):30-8. PubMed ID: 11823755
[TBL] [Abstract][Full Text] [Related]
10. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service.
Weigmann H; Gerek S; Zeisig A; Müller M; Härtter S; Hiemke C
Ther Drug Monit; 2001 Aug; 23(4):410-3. PubMed ID: 11477325
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine-induced retarded ejaculation: role of paroxetine comedication? A case report.
Bizouard P; Vandel S; Kantelip JP
Therapie; 2001; 56(4):443-5. PubMed ID: 11677871
[No Abstract] [Full Text] [Related]
12. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.
D'Amico G; Cedro C; Muscatello MR; Pandolfo G; Di Rosa AE; Zoccali R; La Torre D; D'Arrigo C; Spina E
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):619-23. PubMed ID: 12787848
[TBL] [Abstract][Full Text] [Related]
13. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine.
Zullino DF; Delessert D; Eap CB; Preisig M; Baumann P
Int Clin Psychopharmacol; 2002 May; 17(3):141-3. PubMed ID: 11981356
[TBL] [Abstract][Full Text] [Related]
14. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients.
Kinon BJ; Stauffer VL; McGuire HC; Kaiser CJ; Dickson RA; Kennedy JS
J Am Med Dir Assoc; 2003; 4(4):189-94. PubMed ID: 12837139
[TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.
Lucas RA; Gilfillan DJ; Bergstrom RF
Eur J Clin Pharmacol; 1998 Oct; 54(8):639-43. PubMed ID: 9860152
[TBL] [Abstract][Full Text] [Related]
16. The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine.
Haslemo T; Refsum H; Molden E
Br J Clin Pharmacol; 2011 Apr; 71(4):611-5. PubMed ID: 21395655
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication.
Gex-Fabry M; Balant-Gorgia AE; Balant LP
Ther Drug Monit; 2003 Feb; 25(1):46-53. PubMed ID: 12548144
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine: another psychotropic?
Davis MP; Dickerson ED
Am J Hosp Palliat Care; 2001; 18(2):129-32. PubMed ID: 11407129
[TBL] [Abstract][Full Text] [Related]
19. Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid.
Mao M; Skogh E; Scordo MG; Dahl ML
J Clin Psychopharmacol; 2012 Apr; 32(2):287-9. PubMed ID: 22388157
[No Abstract] [Full Text] [Related]
20. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex.
Zhang W; Perry KW; Wong DT; Potts BD; Bao J; Tollefson GD; Bymaster FP
Neuropsychopharmacology; 2000 Sep; 23(3):250-62. PubMed ID: 10942849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
